Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008:2:39-45.
doi: 10.2174/1874306400802010039. Epub 2008 May 15.

Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study

C P Simeón-Aznar  1 , V Fonollosa-Plá, C Tolosa-Vilella, A Selva-O Callaghan, R Solans-Laqué, E Palliza, X Muñoz, M Vilardell-Tarrés
Affiliations

Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study

C P Simeón-Aznar et al. Open Respir Med J. 2008.

Abstract

Objective: Interstitial lung disease (ILD) frequently complicates systemic sclerosis (SSc). Cyclophosphamide (CYC) is a promising immunosuppressive therapy for SSc-related ILD. Our objective was to investigate the effectiveness of an intravenous CYC (iv CYC) pulse regime in SSc-related ILD during treatment and thereafter.

Methods: In a prospective observational study ten consecutive patients with SSc-related ILD were treated with iv CYC in a pulse regime lasting from 6 to 24 months. Clinical status, pulmonary functional testing (PFT) and high resolution computed tomography (HRCT) of the chest were evaluated at enrolment and 6, 12 and 24 months thereafter. After treatment withdrawal, patients were followed up every 6 months with PFT and chest HRCT to monitor lung disease.

Results: Clinical improvement was apparent in 8 out of 10 patients. The median values of forced vital capacity (FVC), forced expiratory volume in the first second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) as well as ground-glass pattern on HRCT did not change significantly after 6, 12 and 24 months of therapy. The follow-up continued in 8 out of 10 patients after treatment withdrawal for a median of 26.5 months (range: 12-48 months). The final median FVC was 54.5% of predicted value (interquartile range, IQR= 31.6%-94%). Only one patient suffered a FVC deterioration greater than 10%, even though less than 160 ml. The final median DLCO was 68% of predicted value (IQR=38.3-83.6%). Only 2 patients who developed pulmonary arterial hypertension deteriorated their DLCO values of more than 15%.

Conclusions: An iv CYC pulse regimen over 24 months may stabilize pulmonary activity in patients with SSc-related ILD during the course of treatment and for a median of 26.5 months thereafter.

Keywords: Systemic sclerosis; cyclophosphamide.; interstitial lung disease.

PubMed Disclaimer

Figures

Fig. (1).
Fig. (1).
FVC did not change significantly during follow-up.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin N Am. 2003;29:371–390. - PubMed
    1. Jacobsen S, Ullman S, Shen GQ, et al. Influence of clinical features serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol. 2001;28:2454–59. - PubMed
    1. Steen V, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437–44. - PubMed
    1. Altman R, Medsger TA Jr, Bloch D, et al. Predictors of survival in systemic sclerosis (scleroderma) Arthritis Rheum. 1991;34:403–13. - PubMed
    1. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival on patients with fibrosing alveolitis. Rheumatology (Oxford) 2002;41:676–9. - PubMed

LinkOut - more resources